Some patients who submitted for NGS testing used a small 8-gene panel covering only the classic NSCLC oncogenic genes: EGFR, ALK, BRAF, ERBB2, KRAS, MET, ROS1, and RET, and did not interrogate TP53 and RB1, which are genes commonly altered in LCNEC [36, 38–40]. The gene discussed is ERBB2; the disease is large cell neuroendocrine carcinoma.